We provide detailed clinical, virological, and immunological data of a B-cell–depleted patient treated with obinutuzumab for follicular lymphoma with protracted coronavirus disease 2019 (COVID-19) and viremia. A sustained response was achieved after 2 courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.
CITATION STYLE
Malsy, J., Veletzky, L., Heide, J., Hennigs, A., Gil-Ibanez, I., Stein, A., … zur Wiesch, J. S. (2021). Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell–Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 73(11), E4020–E4024. https://doi.org/10.1093/cid/ciaa1637
Mendeley helps you to discover research relevant for your work.